A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
B-cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular
Lymphoma, B-cell Marginal Zone
Waldenstrom Macroglobulinemia
Lymphoma, Mantle Cell

Interventions

DRUG: LY4152199 - IV

Sponsor

Eli Lilly and Company